ArticleOncology letters2014
Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study.
Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Systematic review about complementary medical hyperthermia in oncology.Clinical and experimental medicine · 2022Pooled it
- Bioelectromagnetism for Cancer Treatment-Modulated Electro-Hyperthermia.Current oncology (Toronto, Ont.) · 2025Review
- Modulated electro-hyperthermia therapy combined with Korean mistletoe extract treatment exerts a strong anti-tumor activity by enhancing cellular and humoral immune responses in mice.Animal cells and systems · 2025Article
- Review
- Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma.Cancers · 2023Review
- Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system.World journal of gastrointestinal oncology · 2021Review
- Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms.International journal of molecular sciences · 2021Review
- Relationship between Energy Dosage and Apoptotic Cell Death by Modulated Electro-Hyperthermia.Scientific reports · 2020Article
- Quo Vadis Oncological Hyperthermia (2020)?Frontiers in oncology · 2020Review
- Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study.Frontiers in oncology · 2020Article
- Modulated Electrohyperthermia: A New Hope for Cancer Patients.BioMed research international · 2020Review
- Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist.Frontiers in oncology · 2019Review
- Modulated electro-hyperthermia-enhanced liposomal drug uptake by cancer cells.International journal of nanomedicine · 2019Article
- Article
- Article
- Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.International journal of molecular sciences · 2017Article
- In vitro comparison of conventional hyperthermia and modulated electro-hyperthermia.Oncotarget · 2016Article
- Comparison of biological effects of modulated electro-hyperthermia and conventional heat treatment in human lymphoma U937 cells.Cell death discovery · 2016Article
- Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy.BMC cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. Hyperthermia inhibits angiogenesis and promotes apoptosis. Potential synergic antiangiogenic and proapoptotic effects represent the rationale for combining sorafenib with electro-hyperthermia (EHY) in HCC. A total of 21 patients (median age, 64 years; range, 55-73 years) with advanced HCC were enrolled in the current study between February 2009 and September 2010. EHY was achieved by arranging capacitive electrodes with a deep hypothermia radiofrequency field of 13.56 Mhz at 80 W for 60 min, three times per week for six weeks, followed by two weeks without treatment, in combination with sorafenib at a dose of 800 mg every other day. According to the modified Response Evaluation Criteria in Solid Tumors criteria, 50% achieved stable disease, 5% achieved partial response and 45% achieved progressive disease. No complete response was observed. The progression-free survival (PFS) rate at six months was 38%, while the median PFS and overall survival times were 5.2 [95% confidence interval (CI), 4.2-6.2) and 10.4 (95% CI, 10-11) months, respectively. The overall incidence of treatment-related adverse events was 80%, predominantly of grade 1 or 2. Grade 3 toxicity included fatigue, diarrhea, hand-foot skin reaction and hypertension. In the present study, the sorafenib plus EHY combination was feasible and well tolerated, and no major complications were observed. The initial findings indicated that this combination offers a promising option for advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.